PAMPA Study
Preventing arthritis in an at-risk psoriasis cohort (Recruiting Soon)
Type
Interventional – treatment OR observational
Purpose
Approximately 1 in 3 people with skin psoriasis will go on to develop psoriatic arthritis (PsA), but we currently do not know who may develop psoriatic arthritis and why.
The purpose of this study is to is to determine whether a medication given for the treatment of psoriasis, guselkumab (Tremfya), can help slow or prevent the development of PsA in a high-risk psoriasis population.
Eligibility
You may be eligible for this study if you:
- Are aged 18 or older;
- Have been diagnosed with psoriasis; and
- Meet the study’s definition of “high-risk” (significant body surface area covered by psoriasis, with certain findings on your screening ultrasound).
Participation
Participants will be randomized to receive either guselkumab (Tremfya) for 24 months OR placebo for 6 months, then guselkumab for 18 months. You will receive active study drug at some point, and you will be allowed to continue some types of stable non-biologic treatment throughout the 24 months! If you do not want to receive the study drug, you may choose to participate in the control group.
You will be followed over the course of two years, with several in-person clinic visits.
You will have a full musculoskeletal ultrasound at Screening and 6 Months.
You will also complete questionnaires throughout your participation to tell us how you’re doing.
You will receive compensation for your time at the in-person study visits.